A NEW VALUE PROPOSITION OF SMART DEVICES: ADVANCED MEDICATION ADHERENCE MONITORING IN CLINICAL TRIALS

Citation: Schneider A, “A New Value Proposition of Smart Devices: Advanced Medication Adherence Monitoring in Clinical Trials”. ONdrugDelivery Magazine, Issue 79 (Oct 2017), pp 5-9.

Andreas Schneider explores a new value proposition of smart injection systems, introducing how advanced adherence monitoring services resolve some of the key challenges of clinical research practice regarding costs, adherence, data quality and integrity, Dr Schneider explains which technical features are needed for smart devices to provide value-adding adherence monitoring services, using SmartPilot for YpsoMate as a case study.

“Correct dose administration according to the study protocol is at the heart of assessing safety and efficacy endpoints for new investigational drugs…”

HOW TO MAXIMISE THE VALUE CREATION OF SMART DEVICES

Healthcare is one of many industries being transformed by innovative digital products and services. Although healthcare may seem to lag behind others in unleashing the full potential of smart connected technologies, pharmaceutical companies and device manufacturers are vigorously pursuing joint R&D programmes to develop novel digital solutions. For example, with the ever-growing global diabetes pandemic, particular efforts are being made to lower the cognitive and emotional burden of insulin therapy with the help of smart devices and digital health platforms. Other therapeutic areas that require repeated self-administration will also benefit, such as hypercholesterolaemia, asthma or rheumatoid arthritis.

Although emerging trends toward outcome-based payment systems, real-time therapy monitoring and patient convenience are driving innovators to develop digital solutions that accelerate drug product market uptake, value propositions may remain vague for patients, healthcare professionals and payers. Tracking medication events and wirelessly transmitting such data to health platforms reflects a necessary, yet insufficient, condition to trigger behavioural change and in turn improve therapy outcomes. It is thus important to shed more light on the value proposition of smart devices for adherence monitoring in clinical trials. In fact, some of the most pronounced challenges investigators and participants are confronted with in large multi-centre trials relate to the absence of advanced adherence monitoring services.

CHALLENGES IN CLINICAL RESEARCH PRACTICE TODAY

Investigators face many obstacles that, in sum, reduce the motivation to participate in clinical research. These hurdles start with the recruitment of suitable patients but more significantly relate to the administrative burden of conducting and documenting clinical research. Due to busy patient practices, investigators typically devote little time to actual research. They need to complete large amounts of paperwork, prepare for regular audits and reviews, or are confronted with the ever increasing complexity of visit schedules and assessments. Efforts are made to understand whether patients’ routine administration of the investigational drug is in line with the study protocol.

“SmartPilot enables authentication of the combination product at the point-of-use. As such, it may alert users in case a batch of investigational drug has to be corrected or removed from the clinical trial…”

Current practices advise investigators and study personnel at each site to assess adherence using dosage counts or data patients have captured manually, which are then transferred to the source document after each visit. Phone calls are required to remind patients to take the investigational drug according to the injection schedule or clarify questions. There are also key challenges in tracking whether the correct presentation of the investigational drug was allocated to the assigned treatment arm and recorded in the source document accordingly. For instance, investigators have to detach part of the product label manually and affix it to the patient’s unique number in the corresponding source document before dispensing the packaging to the patient.

Similarly, patients value participation in clinical trials based on their perceived individual cost-benefit ratio. Despite today’s multi-centre set-up of clinical trials, travelling to the nearest study site may still take up significant time and impose costs. This is particularly relevant if such visits relate to simply monitoring health status, filling in questionnaires or performing dose administration. Furthermore, there is the latent risk of missing doses and hampering the validity of the study. In fact, patients are typically asked to record medication intake manually and inform about dose schedule adjustments or interruptions during the study. As such, the burden of extensive paperwork for patients is not limited to the informed consent process but continues throughout the trial.

Also, there is an overall trend to reduce the injection frequency of novel second-generation biological drugs. Although the added convenience compared with first generation medications is obvious, investigators are confronted with patients forgetting how to perform the procedure between injections. This may provoke handling errors, trigger additional interactions with trials centres and further diminish overall adherence.

“SmartPilot enables advanced adherence tracking services without requiring any physical modification to YpsoMate…”

CROs are similarly under pressure to reduce costs and optimise logistics for clinical trial monitoring. These activities target supplies strategy and planning, expiry management or return and destruction of investigational drug supplies. Most importantly, complexities also arise with trial site and patient management, such as patient enrolment and visits, treatment allocation, dosing and dispensing.

Currently there is no mechanism available targeting adherence data quality and integrity or data collection mechanisms. This is all the more surprising in that correct dose administration according to the study protocol is at the heart of assessing safety and efficacy endpoints for new investigational drugs.

SMART DEVICE REQUIREMENTS FOR ADHERENCE MONITORING SERVICES

Figure 1: SmartPilot for YpsoMate (right) is a reusable smart add-on, transforming the two-step autoinjector YpsoMate into a fully connected combination product. Advanced sensing capabilities to track device usage and guide patients through the injection process are at the heart of effective adherence monitoring. Relevant injection data is then transmitted to a gateway, such as a hub or mobile app (left), to be made available to clinical trial sites.

Smart devices must feature certain sensing capabilities in order to be used as effective advanced adherence monitors. Let me illustrate these core requirements with SmartPilot for YpsoMate, a reusable add-on that transforms the proven and unchanged two-step auto-injector platform into a fully connected smart product system (Figure 1).

At its heart, SmartPilot contains a contactless sensor solution that differentiates between various states of the two-step auto-injector platform. In so doing, SmartPilot not only tracks whether an injection event has occurred according to the medication schedule but also whether that injection was successfully completed. Additionally, it can guide patients step-by-step through the injection process. Guidance includes direct visual and audible feedback on the SmartPilot add-on itself or the remote real-time display of the instructions for use on a companion mobile app.

Figure 2: The clinical trial adherence monitoring dashboard sheds light on the two critical dimensions of adherence monitoring throughout clinical trials: injection schedule, as per study protocol, and correct dose administration. The summary report enables real-time monitoring of adherence patterns and, for instance, allows swift action to be taken if handling errors accumulate at certain clinical trial sites.

SmartPilot adds another dimension to patient guidance: it identifies investigational drugs, tracks medication allocation to treatment arms, and thereby simplifies clinical trial supply monitoring. SmartPilot enables authentication of the combination product at the point-of-use. As such, it may alert users in case a batch of investigational drug has to be corrected or removed from the clinical trial.

Most importantly, SmartPilot enables advanced adherence tracking services without requiring any physical modification to YpsoMate. The same auto-injector configuration can be used flexibly with SmartPilot for clinical trials or without for commercial drug product.

SmartPilot sensing capabilities enable a number of value-adding adherence monitoring services during clinical trials. In doing so, SmartPilot sets the foundation for more patient-centric clinical trial design. Advanced notification and reminding services not only reduce the frequency of patient visits but also help to increase patient interest and enrolment in trials. Furthermore, automated adherence data tracking significantly reduces the administrative burden at clinical trial sites. For instance, certain sites may configure an automated alert if a patient repeatedly injects a partial dose only.

Table 1 summarises SmartPilot’s core functionalities as related to the various stakeholders’ value propositions.

The ability to monitor the progress of clinical trials in real-time is equally important to CROs and pharmaceutical sponsors. Remote trial monitoring dashboards may include insights into detailed patient adherence patterns. Innovative decision-making tools enable CROs to quickly respond to, and take appropriate measures against, emerging peculiarities in adherence patterns during clinical trials (Figure 2). For instance, CROs may think of device training and education seminars at certain clinical sites should handling errors accumulate over time.

 SmartPilot Capabilities Description Benefits
 For CROs For Investigators / Study Site For Participants / PatientsFor Pharma Companies
Tracking injection time/dateAdvanced sensor to automatically track and wirelessly transmit date/time of injection events

Remotely monitor adherence to injection schedule as defined in study protocol

 

Real-time access to usage patterns “outside visits”

 

Define measures based on detailed insights (e.g. adherence patterns per site)

 

Reduced efforts in site and patient management

 

Overview of patient IDs at risk of exclusion due to non-adherence

Automated data capturing in source document/ case report form

 

Automated patient reminder/ notification systems

 

Remote adjustments to participants’ medication schedule

 

Automated notification services (e.g. in case a patient risks exclusion from study)

Convenience through automated entries in injection diary

 

Reminder and notification services

 

Ensuring medication schedule is up-to-date

 

Overview of injection history and schedule of future injections

Automated adherence tracking to improve overall data quality and integrity

 

Real-time overview of adherence data “outside” visits

 

Cost efficiencies due to lower administrative overhead/shorter duration of clinical trials

 

Prevent patient exclusion due to non-adherence (injection schedule)

Step-by-step patient guidanceGuide patients real-time and step-by-step through the instructions for use, advise on critical use steps, and inform about potential handling errors, if any

Implement specific measures at study site (e.g. device training campaigns due to unusual usage patterns)

 

Insights into use patterns per treatment arm/study site

Notification services in case of repeated use errors (i.e. “call to action”)

 

Automated patient interaction on device usage throughout clinical trials

Further confidence in effectively using devices

 

Avoid use errors due to forgetting proper procedure between injection events

 

Less travelling to study site to administer drug

Complete picture of adherence, including actual device usage

 

Real-time insights into usage patterns across sites (i.e. differences in  geographies/ countries)

 

Prevent patient exclusion due to non-adherence (device usage)

Identification of drug productAuthentication of investigational drug product based on unique identification number

Track-and-trace of investigational drug to increase transparency of drug supply

 

Additional efficiencies in trials monitoring

Confirm correct allocation of investigational drug to treatment arm

 

Automated database entries to avoid conflicts between various sources of raw data

Confirmation that correct YpsoMate is at use (e.g. dose strength versus placebo)

 

Alert users in case certain batches have to be corrected or removed from clinical trial

Increase patient safety with track-and-trace solutions

 

Simplify drug allocation to sites and treatment arms

No modification to injection deviceSensor solution does not require any modification to auto-injector mechanics; same configuration used for clinics and commercials

SmartPilot platform adherence monitoring infrastructure used across customer-specific YpsoMate variants

 

Proven auto-injector device used in clinical studies

Known auto-injector platform subjected to advanced adherence tracking services

 

Injection could be performed at study site without smart connected SmartPilot add-on

Same handling concept used for clinical studies as for commercial phase

 

No mechanical interface visible on YpsoMate to avoid patient confusion/ complaints

No change to auto-injector required when moving from connected clinical to commercial configuration

 

SmartPilot platform used as adherence monitoring tools across clinical trial programmes

Table 1: SmartPilot’s sensing capabilities translate into value-added services for key stakeholders in clinical trials.

CONCLUSION

The soaring costs in designing, implementing, and monitoring clinical trials point to a clear need for a fresh approach. New designs are required that minimise administrative tasks at trial sites and reduce the burden of participation on patients. Here, I described how such innovative, patient-centric trial designs can be enabled by advanced adherence tracking services, realised through smart devices. These services facilitate safe and effective self-administration of investigational drugs, enable complete remote patient monitoring and improve the quality and integrity of adherence data (Figure 3).

Figure 3: Overview of how SmartPilot clinical trial monitoring services create value for stakeholders. SmartPilot reduces the burden of participation in, and administration of, clinical trials that in turn creates cost efficiencies for pharmaceutical sponsors and improves data quality and integrity.

This article illustrates how the integration of smart devices in clinical research practice offers a unique value proposition and addresses some of the greatest challenges in performing large multi-centre clinical trials. It also disentangles what sensing capabilities a smart device must have in order to unleash its full potential as an effective clinical trial monitoring aid.

Comment on this article

Top